Vijay Pande — who left a16z’s roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a “discovery” science to an “engineering” one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Related Posts
The most interesting startups right now want to get you off your phone
While the AI fundraising machine keeps breaking its own records, some founders are building in the other direction. Mirror…
Final 3 days to save up to $500 on your TechCrunch Disrupt 2026 pass
Save up to $500 on your TechCrunch Disrupt 2026 pass until April 10, 11:59 p.m. PT. Secure your spot at…
Okta buys AI security startup Permiso; source says for about $200M
The deal gives Okta identity threat detection capabilities as enterprises seek to secure AI agents and other non-human…